Replies to post #54 on Interpace Biosciences Inc. (IDXG)

[Franyeld]

if diagnostic / prevention is the best medicine available in 2016 ( i.e. against widespread cancer , against worse condition later in the path of cures and hospitalization )
then they should be well positioned ....

[zino]

that's huge DD here...nice biotech !!!!

[zino]

Must Read DD !!!!
Results: Four hundred ninety-two cases (66 malignant) with surgical pathology (n=209) or long-term follow-up of 2.0-7.7 yrs (n=283) were analyzed (Table 1). 31/492 initially had HRS; 461/492 initially lacked HRS. Malignancy was found in 58% initially having HRS. Malignancy was found in only 10% initially lacking HRS, but in 30% when 2-3 DNA abnormalities were also initially present, and only 3% when all DNA abnormalities were initially absent. Malignancy was found in 4% initially lacking HRS and all WF, but in 9% when 2-3 DNA abnormalities were also initially present. Malignancy was found in 17% initially lacking HRS and having 1 WF, but in 50% when 2-3 DNA abnormalities were also initially present, and in only 2% when all DNA abnormalities were initially absent. Malignancy was found in 30% initially lacking HRS and having 2 or more WF, but in 80% when 2-3 DNA abnormalities were also initially present, and in only 8% when all DNA abnormalities were initially absent.

Discussion: In the absence of HRS, analysis of pancreatic cysts for TSG mutations, KRAS, and DNA quantity provides value to assessing risk of future malignancy. The presence of 2 or more DNA abnormalities can help identify patients in need of more aggressive management. The absence of all DNA abnormalities can help identify patients in need of less aggressive management.

References: 1. Al-Haddad MA, et al. Endoscopy 2015; 47:1-11.